3SBio Inc., a Chinese biopharmaceutical company, through a joint venture formed with CPE Funds, has acquired the CDMO business of Canada-based biologics manufacturer Therapure Biopharma for $290 million. Through this acquisition, 3SBio intends to enter the North American biopharmaceutical sector, an important milestone towards its strategy of building a leading global biologics business. The acquisition enhances its connections with global biotechnology and pharmaceutical companies, and poten...